Nurix Stock

nurixtx.comHealthcareFounded: 2012Funding to Date: $48.38MM

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels by controlling ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

Register for Details

For more details on financing and valuation for Nurix, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Nurix.

Register Today

Team

Management Team

Nancy Pryer Ph.D
Chief Development Officer
John Kuriyan Ph.D
Co-Founder
Pierre Beaurang Ph.D
Chief Business Officer
Michael Rape Ph.D
Co-Founder
Arthur Sands Ph.D
Chief Executive Officer & Board Member
Arthur Weiss MD
Co-Founder

Board Members

David Lacey MD
Arthur Sands Ph.D
Robert Tjian Ph.D
The Column Group
Timothy Kutzkey Ph.D
The Column Group
Jeffrey Tong Ph.D
Third Rock Ventures

Other companies like Nurix in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B

News

Gilead Sciences is turning to Nurix Therapeutics in an effort to discover new drugs that harness the cellular machinery our bodies use to dispose of